Recent studies have developed SF2523 [24, 25] as a dual inhibitor of BRD4 and PI3K (phosphatidylinositol 3-kinase)-AKT, the latter is another key oncogenic pathway that is vital for RCC initiation and progression [26, 27]. This evidence concerns the gene BRD4 and renal cell carcinoma.